Challenges in IPF diagnosis, current management and future perspectives

Challenges in IPF diagnosis, current management and future perspectives

Authors

  • Athol U. Wells Royal Brompton Hospital, London, UK
  • Ulrich Costabel Ruhrlandklinik, University Hospital, Essen, Germany
  • Venerino Poletti Ospedale GB Morgagni, Forlì, Italy
  • Bruno Crestani Hôpital Bichat-Claude Bernard, Université Paris Diderot, Paris, France
  • Jim Egan Department of Respiratory Medicine, Mater Misericordiea University Hospital, Dublin, Ireland
  • George Margaritopoulos Interstitial Lung Disease Unit, Royal Brompton Hospital and National Heart and Lung Institute, London, UK
  • Katerina Antoniou Department of Thoracic Medicine and Laboratory of Cellular and Molecular Pneumonology, University of Crete, Crete, Greece

Keywords:

idiopathic pulmonary fibrosis, guidelines, staging, cryobiopsy, pirfenidone, genetics

Abstract

Recent developments have clarified our understanding of IPF and improved outcomes with two viable new therapeutic options, pirfenidone and nintedanib. In spite of these advances, questions and challenges concerning IPF still remain. Here we will focus on some of these unresolved areas: the diagnosis of IPF is hindered by limitations in current practice guidelines, surgical lung biopsy is contraindicated in many patients, the accuracy of prognostic evaluation needs to be increased and tolerability factors can jeopardise adherence to treatment. We will also identify new developments shaping the future of IPF management such as cryobiopsy, increased understanding of genetic factors and new treatment paradigms, which may help to fulfil currently unmet needs. (Sarcoidosis Vasc Diffuse Lung Dis 2015; 32; Suppl 1: 28-35)

Downloads

Published

03-08-2015

Issue

Vol. 32 No. 1S (2015): Supplement 1/2015: Advancing IPF Research (AIR) 2014

Section

Review

License

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.

 

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

1.
Wells AU, Costabel U, Poletti V, Crestani B, Egan J, Margaritopoulos G, et al. Challenges in IPF diagnosis, current management and future perspectives. Sarcoidosis Vasc Diffuse Lung Dis [Internet]. 2015 Aug. 3 [cited 2025 Jun. 22];32(1S):28-35. Available from: https://mattioli1885journals.com/index.php/sarcoidosis/article/view/4700